943145-64-0

Basic information

• Product Name: tert-butyl (Z)-5-(2-(benzyloxycarbonylamino)-3-methoxy-3-oxoprop-1-enyl)-1H-indazole-1-carboxylate
• Synonyms: tert-butyl (Z)-5-(2-(benzyloxycarbonylamino)-3-methoxy-3-oxoprop-1-enyl)-1H-indazole-1-carboxylate
• CAS NO: 943145-64-0
• Molecular Weight: 451.479
• Mol File: 943145-64-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: tert-butyl (Z)-5-(2-(benzyloxycarbonylamino)-3-methoxy-3-oxoprop-1-enyl)-1H-indazole-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (Z)-5-(2-(benzyloxycarbonylamino)-3-methoxy-3-oxoprop-1-enyl)-1H-indazole-1-carboxylate(943145-64-0)
• EPA Substance Registry System: tert-butyl (Z)-5-(2-(benzyloxycarbonylamino)-3-methoxy-3-oxoprop-1-enyl)-1H-indazole-1-carboxylate(943145-64-0)

Safety Data

• Hazardous Substances Data: 943145-64-0(Hazardous Substances Data)

Upstream product

• 635713-71-2 tert-butyl 5-formyl-1H-indazole-1-carboxylate 
• 100945-15-1 N-(benzyloxycarbonyl)phosphonoglycine trimethyl ester 

Downstream Products

• 1075706-11-4 methyl (Z)-2-(benzyloxycarbonylamino)-3-(1H-indazol-5-yl)acrylate 

Relevant articles and documents

Catalytic asymmetric syntheses of tyrosine surrogates

(Chemical Equation Presented) Amino acid esters 5-11 as tyrosine mimics have been synthesized in excellent enantioselectivity (up to 99.6% ee) and in good overall chemical yields. The key step in the sequence was the Burk's [Rh(COD)(2R,5R)-Et-DuPhos]BF4-catalyzed asymmetric hydrogenation of enamides with a variety of reactive functional groups.

CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS

The presnt invention relates to compounds of Formula (I), as antagonists of calcitonin gene-related peptide receptors ("CGRP-receptor"), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.